About BriaCell Therapeutics
BriaCell Therapeutics is a company based in Beverly Hills (United States) founded in 2004. The company has 18 employees as of July 31, 2024. BriaCell Therapeutics offers products and services including Bria-IMT, Bria-OTS, and Bria-OTS+. BriaCell Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Beverly Hills, United States
- Employees 18 as on 31 Jul, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Briacell Therapeutics Corp
-
Annual Revenue
Not available
-
Net Profit
-$4.52 M (USD)76.09as on Jul 31, 2024
-
EBITDA
-$31.41 M (USD)-44.81as on Jul 31, 2024
-
Latest Funding Round
$399.92 K (USD), Grant
Sep 01, 2023
-
Investors
HHS
& 4 more
-
Employee Count
18
as on Jul 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BriaCell Therapeutics
BriaCell Therapeutics is a publicly listed company on the TSX with ticker symbol BCT in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BriaCell Therapeutics
BriaCell Therapeutics offers a comprehensive portfolio of products and services, including Bria-IMT, Bria-OTS, and Bria-OTS+.
Targets metastatic breast cancer through immune activation in clinical trials.
Provides off-the-shelf personalized treatment for breast and prostate cancers.
Enhanced version for various cancers, including prostate, via HLA matching.
People of BriaCell Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of BriaCell Therapeutics
Investors in BriaCell Therapeutics
BriaCell Therapeutics has secured backing from 5 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include HHS, National Cancer Institute and Prevail Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Limited information is provided about Prevail Partners' activities.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Cancer research is conducted and supported by the institute.
|
Locked | Locked | Locked |
Investor details for BriaCell Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BriaCell Therapeutics
Investment portfolio details for BriaCell Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BriaCell Therapeutics
Detailed financials for BriaCell Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Briacell Therapeutics Comparisons
Peer comparison for BriaCell Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BriaCell Therapeutics
BriaCell Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of BriaCell Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Briacell Therapeutics
Complete news archive for BriaCell Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BriaCell Therapeutics
BriaCell Therapeutics was founded in 2004 and raised its 1st funding round 10 years after it was founded.
BriaCell Therapeutics is headquartered in Beverly Hills, United States. It is registered at Beverly Hills, California, United States.
As of Jul 31, 2024, the latest employee count at BriaCell Therapeutics is 18.
Developer of immunotherapies for the treatment of cancer. Its lead product candidate, Bria-IMT is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. Bria-IMT is used in combination with multiple immune modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells. Another product Bria-OTS is shelf-personalized immunotherapy for the treatment of advanced-stage breast cancer.
BriaCell Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
BriaCell Therapeutics offers Bria-IMT, Bria-OTS, and Bria-OTS+.
Yes, BriaCell Therapeutics is publicly traded on TSX under the ticker symbol BCT.
BriaCell Therapeutics has 5 investors. Key investors include HHS, National Cancer Institute, Prevail Partners, Wiseman Cancer Research Foundation, and Jamieson Bondarenko.
The ticker symbol of BriaCell Therapeutics is BCT on TSX.